ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0587

The Effects of Allopurinol on the Progression of CKD According to Baseline Kidney Function: Prespecified Analyses of the CKD-FIX Trial

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Tiku, Anushree, George Institute for Global Health, Sydney, New South Wales, Australia
  • Pascoe, Elaine, The University of Queensland, Saint Lucia, Queensland, Australia
  • Boudville, Neil, The University of Western Australia, Perth, Western Australia, Australia
  • Cass, Alan, Menzies School of Health Research, Casuarina, Northern Territory, Australia
  • Dalbeth, Nicola, The University of Auckland Faculty of Medical and Health Sciences, Auckland, Auckland, New Zealand
  • Day, Richard O., St Vincent's Health Australia Ltd, Bondi Junction, New South Wales, Australia
  • de Zoysa, Janak, The University of Auckland Faculty of Medical and Health Sciences, Auckland, Auckland, New Zealand
  • Douglas, Bettina, The University of Queensland, Saint Lucia, Queensland, Australia
  • Faull, Randall, The University of Adelaide Faculty of Health and Medical Sciences, Adelaide, South Australia, Australia
  • Harris, David, The University of Sydney, Sydney, New South Wales, Australia
  • Hawley, Carmel, The University of Queensland, Saint Lucia, Queensland, Australia
  • Jones, Graham R D, University of New South Wales, Sydney, New South Wales, Australia
  • Kanellis, John, Monash University, Clayton, Victoria, Australia
  • Palmer, Suetonia, University of Otago, Dunedin, New Zealand
  • Perkovic, Vlado, George Institute for Global Health, Sydney, New South Wales, Australia
  • Rangan, Gopi, Westmead Hospital, Westmead, New South Wales, Australia
  • Reidlinger, Donna, The University of Queensland, Saint Lucia, Queensland, Australia
  • Robison, Laura, The University of Queensland, Saint Lucia, Queensland, Australia
  • Walker, Robert J., University of Otago, Dunedin, New Zealand
  • Walters, Giles, Australian National University, Canberra, Australian Capital Territory, Australia
  • Johnson, David W., The University of Queensland, Saint Lucia, Queensland, Australia
  • Badve, Sunil, George Institute for Global Health, Sydney, New South Wales, Australia
Background

The CKD-FIX trial showed that allopurinol did not slow the decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with chronic kidney disease (CKD) and risk of progression. In this study, we assessed the effect of allopurinol on change in eGFR according to CKD stage at baseline.

Methods

Three hundred and sixty nine adults with CKD stage 3 or 4, no history of gout, and who were at risk of progression (identified by either urinary albumin-to-creatinine ratio ≥265 mg/g or eGFR decrease ≥3.0 mL/min/1.73 m2 in the preceding year) were randomized to receive allopurinol or placebo. Primary outcome was rate of change in eGFR up to 104 weeks using the CKD-EPI creatinine equation. This pre-specified subgroup analysis describes outcomes in patients with CKD stage 3 and stage 4.

Results

At baseline, 178 (49%) patients had CKD stage 3 (mean eGFR 41 mL/min/1.73 m2, mean serum urate 7.9 mg/dL) and 185 (51%) patients had CKD stage 4 (mean eGFR 23.1 mL/min/1.73 m2, mean serum urate 8.4 mg/dL) . In patients with CKD stage 3, change in eGFR did not differ between the allopurinol (-3.67 mL/min/1.73 m2/year, 95% CI -4.97 to -2.38) and placebo (-3.34 mL/min/1.73 m2/year, 95% CI -4.59 to -2.09) groups (mean difference [MD], -0.33 mL/min/1.73 m2/year, 95% CI -2.13 to 1.47). In patients with CKD stage 4, there was no difference in change in eGFR between the allopurinol (-2.89 mL/min/1.73 m2/year, 95% CI -3.74 to -2.03) and placebo (-2.89 mL/min/1.73 m2/year, 95% CI -3.73 to -2.04) groups (MD, 0.00 mL/min/1.73 m2/year, 95% CI -1.18 to 1.17). The interaction P value for subgroup analysis was 0.87.

Conclusion

In CKD patients at risk of progression, the effect of allopurinol on eGFR decline was not modified by baseline kidney function.

Funding

  • Government Support - Non-U.S.